How is HGH fragment 176-191 dosed and mixed?
250 mcg of hGH Fragment 176-191 from a 5 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water |
|---|---|---|
| 2 mg | 2 mg/mL: 250 mcg is 12.5 units, 500 mcg is 25 units | 1 mg/mL: 250 mcg is 25 units, 500 mcg is 50 units |
| 5 mg | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units | 2.5 mg/mL: 250 mcg is 10 units, 500 mcg is 20 units |
DailyMed lists no label for hGH fragment 176-191, and the oral doses in trials of the related AOD9604 ran from 0.25 mg/day to 54 mg.1
Vial strengths, water and syringe marks
The amounts in the vial table, the worked example and the calculator are example amounts, not figures from any source: no subcutaneous human trial dose appears in the sources read, and the trials gave AOD9604 in mg by mouth or in µg/kg intravenously.1 A manufacturer listing on ChemicalBook offers hGH fragment 176-191 in 2 mg vials,2 and a vendor page for AOD-9604 lists 5 mg vials and says the material is for research use only, not for human use.3 In the two intravenous trials Stier and colleagues (2013) summarised, METAOD001 (15 men) and METAOD002 (23 men), AOD9604 was supplied as a lyophilized powder and reconstituted with the designated volume of sterile water for intravenous injection; no mL figure is given in the text read.1 No label or trial gives a water volume for a vial, so the concentrations in the table are arithmetic on the volumes shown. A review says AOD9604, the compound in the trials below, is often described as hGH 177-191 with an additional N-terminal tyrosine, and is hence sometimes labelled hGH 176-191.4
Worked example: 250 mcg from a 5 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
250 mcg of hGH Fragment 176-191 from a 5 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
250 mcg of hGH Fragment 176-191 from a 5 mg vial mixed with 2 mL is 10 units on a U-100 syringe.
What the trials gave
Stier and colleagues (2013) summarised the six trials below; two of the three authors, Evert Vos and David Kenley, list Metabolic Pharmaceuticals as their affiliation, and the paper thanks Metabolic Pharmaceuticals for funding all six trials.1
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| METAOD005 | Placebo or 1, 5, 10, 20 or 30 mg capsules once daily by mouth | 300 obese adults (men, and women of non-child-bearing potential), 50 per arm | 12 weeks of treatment after a 2-week single-blind placebo run-in, 14 weeks in all1 |
| METAOD006 | Daily tablets of 0.25 mg, 0.5 mg, 1 mg or placebo | 502 obese adults randomized (534 enrolled): 127, 125 and 125 on the three doses, 125 on placebo | 24 weeks after a 4-week single-blind placebo run-in1 |
| METAOD004 | 9, 27 or 54 mg capsules daily by mouth, or placebo | 36 obese men, 9 per arm | seven days1 |
| METAOD003 | Single doses of 9, 27 and 54 mg capsules by mouth or placebo, 2 weeks apart | 17 obese men, 15 completed | single doses1 |
| METAOD001 | Three single intravenous infusions over 20 minutes, doses rising from 25 to 400 µg/kg, and placebo, each 7 days apart, with a single dose of growth hormone as a positive control | 15 healthy men, 14 completed | single doses, with a 7-day washout between them1 |
| METAOD002 | Four single intravenous infusions over 20 minutes, 25, 50 and 100 µg/kg and placebo, each man receiving all four, 7 days apart | 23 obese men | single doses, with a 7-day washout between them1 |
No subcutaneous human trial dose or injection site appears in the sources read, and no cycle length or stacking figure. ClinicalTrials.gov returned no registered study under either name, and a review says the half-life of AOD9604 was not reported in human trials.4
Storage
No label, trial, regulator or review source read gives a storage condition before or after mixing, or any stability data; the only storage figures seen were on supplier and vendor pages.
Frequently asked questions
Is hGH fragment 176-191 banned by WADA?
The WADA 2026 Prohibited List names hGH 176-191 as an example of a growth hormone fragment in class S2, a class prohibited at all times, in and out of competition.5
Is there a different dose for men and women?
No sex-specific dose is stated in the sources read; the 300 obese adults in METAOD005, men and women of non-child-bearing potential, were 54% male and 46% female, and the 502 in METAOD006 were 44% male and 56% female.1 The first four trials, METAOD001 to METAOD004, with 15, 23, 17 and 36 men, included only men.1
Is it injected or taken by mouth?
The trials gave AOD9604 by mouth or intravenously;1 one review says it is generally administered subcutaneously, without citing a trial for that route in the text read,6 while another review lists it with the oral route.4 The app lists the route as SubQ. No human trial dose for that route appears in the sources read.
What safety information is stated?
On its page of substances in compounding that may present significant safety risks, FDA says it lacks sufficient information to know whether AOD-9604 would cause harm when given to humans, and that it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear.7 The trial summary reports that five patients in METAOD005 had a serious adverse event, none considered by the investigator possibly, probably or definitely related to study medication, and that 18 of the 502 adults (3.6%) in METAOD006, the 125 on placebo included, had one.1 It reports no serious adverse event in METAOD001, METAOD002 or METAOD004, and two in METAOD003, both after 54 mg: diarrhoea, deemed possibly related to study treatment, and bronchial pneumonia, deemed unrelated.1
References
- Journal of Endocrinology and Metabolism (Elmer Press). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (J Endocrinol Metab 2013;3(1-2):7-15). 2013. jofem.org
- ChemicalBook supplier listing. HGH 176-191 | China | Manufacturer | Hebei Zhanyao Biotechnology Co. Ltd. m.chemicalbook.com
- Nova-Pept (vendor). AOD-9604 Research Peptide | NovaPept Labs. nova-pept.lovable.app
- PubMed Central. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
- WADA. World Anti-Doping Code International Standard Prohibited List 2026. 2026. wada-ama.org
- PubMed Central. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. 2026. pmc.ncbi.nlm.nih.gov
- US FDA. Substances in Compounding that May Present Significant Safety Risks. 2026. fda.gov